# Start-ups, Life Science and Business in Ticino

# 24th November 2016

# **LAC** Piazza Bernardino Luini 6 CH - 6900 Lugano

From 9.30 am



This conference and workshop is the expression of a joint desire by the organisers, to promote Life Science Start-ups in Ticino. Each organisation is bringing its expertise and knowledge and they will share this in order to support entrepreneurs.

**Agire Foundation,** The Innovation Agency of Southern Switzerland, is a public-private partnership established in 2011. They promote local innovation and entrepreneurship and an increase in economic competitiveness, leading to the creation of high-skilled jobs.

**Swiss HLG** is a group of Healthcare Licensing Professionals working together to serve those actively involved in business development and licensing within the pharmaceutical, biotechnology and healthcare industry. Swiss HLG is a not-for-profit association run by an elected independent board, representing several companies in Switzerland.

Our group is open to the international healthcare and life sciences industries and provides the richest possible environment for business development professionals to network, build strategic relationships, exchange ideas and to share experiences.

Swiss HLG currently has more than 160 members (85% Swiss-based, others from Germany, France, Italy, Spain, UK, Ireland, Netherlands, USA, and South Korea). We have delivered 23 industry conferences, have an excellent national and international reputation for quality and we offer great opportunities for networking, education, and business development. For more information, please visit www.swisshlg.com\_.

**CP Start Up**, the Start-up Promotion Center, is a service promoted by the 'Foundation for the Lugano Faculties of USI'. It is set up in collaboration with the Università della Svizzera Italiana (USI) and with the Scuola Universitaria Professionale della Svizzera Italiana (SUPSI), to assist Swiss and foreign graduates who plan to start innovative companies in Canton Ticino.

**Inartis Network** is one of the eight NTN (National Thematic Networks) supported by the Commission for Technology and Innovation (CTI), the Swiss Agency for the promotion of technology and innovation. The INARTIS NETWORK mission is to create value and jobs across the Swiss Life Sciences economy through innovation. INARTIS NETWORK, a not-for-profit organisation based in Lausanne, focuses on fostering trans-disciplinary R&D projects to deliver "Innovations Made in Switzerland".

Registration is mandatory as places are limited. To secure your place, register at <u>https://www.eventboost.com/e/start-ups-life-science-and-business-in-ticino/3315/</u> Conference fees: CHF 50.-, including lunch.

For any further inquiries, please do not hesitate to contact us at info@swisshlq.com.



## Program

9.30 - 10.00	Registration
10.00 – 10.40	Introduction from Fondazione Agire, CP Start-up, Swiss HLG & Inartis - Life Science - a key sector for Ticino Speaker: Alcide Barberis, Director Fondazione AGIRE – CP Start-up
	- Swiss HLG: an open door to Licensing and Networking in the healthcare arena Speaker: Rachid Benhamza, Board Member, Swiss Healthcare Licensing Group
	- CTI's National Thematic Networks to support Innovation Speaker: Susanne Lauber Fürst, Vice-President Inartis Network
10.40 - 11.00	Prima Lab SA: A success story of a Life Science Start-up Speaker: Federico Roveda, CEO Prima Lab SA
11.00 - 11.20	How do I finance my Start-up? Speaker: Lorenzo Leoni, Managing Partner TiVenture SA
11.20 – 13.00	Introductory sessions
	<ul> <li>Emerging company perspective</li> <li>Speaker: Helmut Kessmann (Head of Business Development, Polyphor &amp; Board Member, T3 Pharma)</li> </ul>
	- <b>Big Pharma / corporate VC perspective</b> Speaker: Markus Goebel (Managing Director, Novartis Venture Fund)
13.00 - 14.00	Lunch and networking
14.00 – 14.15	Farma Industria Ticino (FIT): overview How do I finance my Start-up? Speaker: Giorgio Calderari, President FIT

## 14.15 – 15.45 Workshop Swiss HLG "Partnering - Create value without dilution"

## Practical case studies (case A and B)

**Case A:** Company has in-licensed from a University, an advanced pre-clinical asset which addresses a high medical need in the CNS area. The product has completed a 4 week toxicology study and is planned to be administered chronically; proof-of-concept has been shown in well accepted animal models. Company estimates another 18 - 24 months until IND filing. Chronic (and other mandatory) toxicological studies will be done later in parallel to a 4 week Phase II clinical study. Peak sales are estimated as 500 mUSD. Estimated development costs until POC in man (Phase II) is 25 mCHF; cash available is 5 mCHF.

**Case B**: Company has developed a novel platform technology for efficient generation of a proprietary variation of antibodies. It has selected oncology as its R&D focus and plans to close collaborations outside the core area. For its first own product, initial proof-of-concept has been shown in an oncology indication. Estimated development costs for a first product until POC in man (Phase I/II) is 20 mCHF; cash available is 3 mCHF, revenue forecast through collaborations 2 mCHF p.a. next 3 years.

#### 15.45 – 16.00 **Conference Conclusion and closing** Speaker: Alcide Barberis, Director Fondazione AGIRE – CP Start-up



Organisers:





In collaboration with:





Sponsors:

